Check out our most popular compounded medications! Get Started
Licensed to fill prescriptions for patients in RI, MA, CT, NJ, NH, FL, ME and PA. New York patients are served on a limited basis while nonresident registration is pending.
Prepared to a prescriber's order for one patient. Not FDA-approved.
This is a compounded liquid for feeding-tube use containing clopidogrel bisulfate, prepared to a prescriber's order for one patient. Compounded preparations are not FDA-approved.
These listings cover every salt or ester form of each drug in the FDA National Drug Code Directory.
FDA-approved products containing clopidogrel are listed in tablet form. No clopidogrel product of any kind is listed in liquid form.
Liquid bases can be aqueous or nonaqueous, and USP <795> classifies the preparation by its water activity. Aqueous preparations carry shorter default beyond-use dates than nonaqueous ones. The date printed on the label is the one to follow.
Clopidogrel is an antiplatelet P2Y12 inhibitor that compounding pharmacies prepare by prescription as oral liquids for patients who cannot use tablets.
Clopidogrel is a P2Y12 platelet inhibitor. It is a prodrug that the body converts, mainly through the liver enzyme CYP2C19, to an active metabolite that irreversibly blocks the platelet ADP receptor, so platelets are less able to clump together for the rest of their lifespan. Plavix (clopidogrel tablets, Sanofi) is FDA-approved to reduce the rate of heart attack and stroke in acute coronary syndrome, including unstable angina and non-ST-elevation and ST-elevation heart attacks, and in patients with a recent heart attack, recent stroke or established peripheral arterial disease. StatPearls notes the manufactured product is an oral tablet only. A prescriber may order clopidogrel compounded when a patient needs a liquid or a strength that is not manufactured. Compounded preparations are not FDA-approved and require a prescription.
Plavix carries a boxed warning: its antiplatelet effect is reduced in people with two loss-of-function copies of the CYP2C19 gene (poor metabolizers), and a genetic test can identify them. Clopidogrel raises bleeding risk; do not use it with active bleeding such as a stomach ulcer or bleeding in the brain, or if you are allergic to it. Stopping early raises the risk of heart attack and stroke, so do not stop without your prescriber; it may be held about 5 days before surgery. Avoid omeprazole and esomeprazole. NSAIDs, warfarin, SSRIs, SNRIs and other antiplatelet drugs add to bleeding risk, and opioids lower clopidogrel exposure. A rare blood disorder (TTP) has been reported. Pregnancy data have not shown a drug-associated risk of birth defects. LactMed reports minute milk levels and no infant effects in limited cases. Talk to your prescriber or pharmacist about black stools or unusual bruising.
Per the Plavix label, absorption is at least 50%. About 85% of circulating metabolites are an inactive carboxylic acid formed by esterases; the active thiol metabolite is formed mostly by CYP2C19, with contributions from CYP1A2, CYP2B6 and CYP3A, and peaks 30 to 60 minutes after dosing. Parent half-life is about 6 hours and active metabolite half-life about 30 minutes; about 50% of a radiolabeled dose is excreted in urine and 46% in feces. Food lowered active metabolite peak concentration without changing its AUC. Strong CYP2C19 inducers such as rifampin increase active metabolite levels and platelet inhibition, and the label advises avoiding them; clopidogrel raises levels of repaglinide (a CYP2C8 substrate), and the label advises avoiding that combination when possible. Labeled indications: Plavix for non-ST-elevation and ST-elevation acute coronary syndrome, and for recent MI, recent stroke or established peripheral arterial disease. StatPearls lists off-label use in PCI, atrial fibrillation, symptomatic carotid stenosis and after CABG. The label advises considering another P2Y12 inhibitor in identified CYP2C19 poor metabolizers. Dosing is per prescriber. Monitor for bleeding, hemoglobin and hematocrit (StatPearls). Clopidogrel is not a controlled substance.
Shake the bottle if your label says to. Draw the dose into the syringe provided. Flush the tube with water before giving the dose, give the medication, then flush again with water as your care team directs. Give each medication separately unless told otherwise. Never give slow release or extended release products through a tube.
G tube liquids are usually aqueous. Under USP <795>, a preserved aqueous preparation carries a beyond-use date of up to 35 days and an unpreserved one 14 days refrigerated. Your label shows whether to refrigerate and the beyond-use date. Keep out of reach of children and discard after that date.
This formulation is compounded by Bayview Pharmacy on a prescriber's order for an individual patient. It is not an FDA-approved drug product, and the FDA has not evaluated it for safety, effectiveness, or manufacturing quality.
A valid prescription is required. Availability depends on Bayview's licensure in your state. This page is general information, not medical advice. Discuss your situation with a licensed healthcare provider.
Search by NCPDP 4106882, or by name and ZIP: Bayview Pharmacy, Warwick, RI 02886. Select it as the destination pharmacy and save it as a favorite. Click any value to copy it.
Compounded preparations have no NDC, so this formula will not appear in your EHR's drug search. Use your system's compound, non-formulary, or free-text prescription entry and name the preparation exactly as written in step 3. If your EHR forces you to pick a listed drug, pick the closest entry for the active ingredient and put the full formula in the prescription body (the Sig or directions field), not in Notes to Pharmacy.
Compounded preparations have no NDC and will not appear in your drug search. For EPCS to validate, select a drug entry your EHR recognizes as controlled, usually the bulk powder entry for the active ingredient (for example Ketamine (bulk) powder, not a branded product), then put the full formula from step 3 in the prescription body. A free-text entry that does not validate as controlled will be rejected by your EPCS module.
Quantity and directions are starting points for this dose form, not treatment recommendations. Dosing remains the prescriber's responsibility.
Transmit from your EHR. For this non-controlled preparation we also accept fax to (401) 284-4506 and phoned orders at (401) 284-4505. Order forms are on the formulation pages and in the prescriber portal.
Transmit with two-factor authentication through your EPCS-enabled EHR. No order form is offered for this preparation; e-prescribing guides for our controlled preparations are on the formulation pages.
Licensed to dispense in RI, MA, CT, NJ, NH, FL, ME, and PA; New York is served on a limited basis while nonresident registration is pending. Compounded preparations are not FDA-approved. A valid prescription is required. Full guide, including steps by EHR: How to e-prescribe to Bayview. Questions about this formula: call (401) 284-4505.
